Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Underwriters in Life Sciences Debt Offering

June 3, 2016

NEW YORKCovington advised the underwriters in connection with Repligen’s $115 million debt offering. The senior convertible notes due in 2021 were placed at 2.125 percent.

Repligen is a bioprocessing company focused on the manufacture of Protein A ligands used by life science companies to purify biologic drugs such as monoclonal antibodies, recombinant proteins, and vaccines.

The Covington corporate team included corporate partners Don Murray and Brian Rosenzweig, with associates Ciarra Chavarria, Matt Gehl, and Laura Torre. Advice was also provided by special counsel Marianne McKeon (FINRA), partner Robert Amaee, with associate Ian Redfearn (FCPA due diligence), partner Paul Berman (IP), partner Rob Heller (tax); and partner Gus Caywood (legal opinion matters).


Share this article: